

PharmaForum - 3. November 2010 in Mainz

1. Company

DAIICHI SANKYO is a global pharmaceutical company that focuses on research and the marketing of innovative medications. The company was created in 2005 through the merger of Daiichi and Sankyo, whose history reaches back to 1899. With net sales of nearly € 7.3 billion in fiscal year 2009, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo. Its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries, and one of its global manufacturing sites is located in Pfaffenhofen, Bavaria.

For more information, please contact:

Dr. Joachim Haes, Leiter Hauptstadtbüro

Ebertstraße 2, 10117 Berlin

Tel. 030 2300 4195, joachim.haes@daiichi-sankyo.de

2. Core Competences

The company's research activities focus on the areas of cardiovascular diseases, hematology, anti-infectives and cancer. Its aim is to develop medications that are best in their class or create a new class of active ingredients.

3. Cooperations offered and requested

DAIICHI SANKYO has a successful history of licensing pharmaceuticals in and out and has acquired the Biotech company U3 Pharma in Martinsried in 2008. We are therefore continuously interested in research as well as marketing cooperations for promising medications.